Trimmel, Bettina
Oszwald, Andre
Diemand, Christoph
Ertl, Iris E.
Lemberger, Ursula
Bruchbacher, Andreas
Brettner, Robert
Korn, Stephan
Resch, Irene
Comperat, Eva
Shariat, Shahrokh F.
Hassler, Melanie R.
Funding for this research was provided by:
Richard Übelhör Grant (2019)
Article History
Received: 7 January 2022
Accepted: 20 July 2022
First Online: 28 July 2022
Competing interests
: SFS reports honoraria for lectures/consulting boards for Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, Ipsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Richard Wolf Roche, Sanochemia, Sanofi, Takeda, Urogen; patents: method to determine prognosis after therapy for prostate cancer granted 2002-09-06, methods to determine prognosis after therapy for bladder cancer granted 2003-06-19, prognostic methods for patients with prostatic disease granted 2004-08-05 and soluble Fas urinary marker for the detection of bladder transitional cell carcinoma granted 2010-07-20. The other authors have no competing interests to declare that are relevant to the content of this article.